Recently, our group demonstrated that CWP232228 (U.S. Patent 8,101,751 B2), a small molecule synthetic compound that antagonizes the binding of β-catenin to TCF in the nucleus, suppresses tumor formation and metastasis without toxicity through the inhibition of the growth of breast CSCs and bulk tumor cells in vitro and in vivo [29]. Here, HNF4A is linked to neoplasm.